SCHEMBL2773210

SCHEMBL2773210

CCCCCCCCCCC(=O)C(=O)N[C@H](CCC(=O)O)C(=O)NCC

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLA2G2A P14555 6/20 0.58
PLA2G5 P39877 3/20 0.58
PLA2G4A P47712 1/20 0.52
NOD1 Q9Y239 1/20 0.47
PLA2G2C Q5R387 1/20 0.47
PLA2G10 O15496 1/20 0.44
PPARG P37231 3/20 0.43
PPARD Q03181 3/20 0.43
PPARA Q07869 3/20 0.43
TSHR P16473 2/20 0.43
GPR84 Q9NQS5 2/20 0.43
HDAC11 Q96DB2 2/20 0.43
TDP1 Q9NUW8 2/20 0.43
ALDH1A1 P00352 1/20 0.43
SLC22A6 Q4U2R8 1/20 0.43
SLC22A8 Q8TCC7 1/20 0.43
TLR2 O60603 1/20 0.43
MEN1 O00255 1/20 0.43
ESR1 P03372 1/20 0.43
FABP4 P15090 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2773206 1.00 PLA2G2A (0.58) PLA2G2APLA2G5PLA2G4ANOD1PLA2G2C
SCHEMBL2773637 1.00 PLA2G2A (0.58) PLA2G2APLA2G5PLA2G4ANOD1PLA2G2C
SCHEMBL2771859 0.90 PLA2G2A (0.62) PLA2G2APLA2G5PLA2G4AALDH1A1MEN1
SCHEMBL2771857 0.90 PLA2G2A (0.62) PLA2G2APLA2G5PLA2G4AALDH1A1MEN1
SCHEMBL2770844 0.88 PLA2G2A (0.68) PLA2G2APLA2G5PLA2G4ANOD1PLA2G2C
SCHEMBL2770848 0.88 PLA2G2A (0.68) PLA2G2APLA2G5PLA2G4ANOD1PLA2G2C
SCHEMBL13286584 0.84 FOLH1 (0.44)
SCHEMBL13286593 0.84 FOLH1 (0.44)
SCHEMBL2117116 0.83 PLA2G2A (0.63) PLA2G2APLA2G5PLA2G4ANOD1PLA2G2C
SCHEMBL2117121 0.83 PLA2G2A (0.63) PLA2G2APLA2G5PLA2G4ANOD1PLA2G2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7745489-B2 Compositions and methods for inhibition of phospholipase A2 mediated inflammation THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2010-06-29 US disclosed
EP-1490328-A4 COMPOSITIONS AND METHODS FOR INHIBITION OF PHOSPHOLIPASE A2 MEDIATED INFLAMMATION UNIV CALIFORNIA (US) 2007-08-15 EP disclosed
US-20050148549-A1 Compositions and methods for inhibition of phospholipase a2 mediated inflammation NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2005-07-07 US disclosed
EP-1490328-A1 COMPOSITIONS AND METHODS FOR INHIBITION OF PHOSPHOLIPASE A2 MEDIATED INFLAMMATION The Regents of The University of California (US) 2004-12-29 EP disclosed
WO-2003076389-A1 COMPOSITIONS AND METHODS FOR INHIBITION OF PHOSPHOLIPASE A2 MEDIATED INFLAMMATION THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2003-09-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050148549-A1 Compositions and methods for inhibition of phospholipase a2 mediated inflammation PLA2G4A, PLA2G4B, PLA2G1B PLA2G2A 5/4885PLA2G5 8/4885PLA2G4A 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.